Form 4: Novavax Director Converts RSUs to Common Stock

Novavax Director Richard J. Rodgers converted 3,800 Restricted Stock Units into common stock, increasing his direct beneficial ownership.

Summary

• Richard J. Rodgers, a Director of Novavax, Inc. (NVAX), acquired 3,800 shares of common stock.
• This acquisition resulted from the conversion of 3,800 Restricted Stock Units (RSUs) on October 29, 2025.
• The RSUs were granted on October 29, 2022, and vested one-third on each of the first three anniversaries of the grant date, subject to continued employment.
• Following this transaction, Rodgers directly beneficially owns 28,490 shares of common stock.

Sentiment

Score: 7

Explanation: The transaction is a routine, expected conversion of equity compensation, indicating continued director alignment with shareholder interests. It's a neutral to slightly positive signal due to increased direct ownership, but does not reflect new operational or financial performance.

Positives

• A director converting Restricted Stock Units (RSUs) to common stock indicates continued alignment of interests with shareholders.
• Increased direct beneficial ownership by a director can be seen as a vote of confidence in the company's future prospects.

Future Outlook

The vesting schedule of the Restricted Stock Units indicates a long-term incentive structure for the director, aligning their interests with the company's future performance. The transaction date of October 29, 2025, is a future date, suggesting this filing is a forward-looking report of a scheduled vesting event.

Industry Context

This is an insider transaction filing, which is a common occurrence across all publicly traded companies. It reflects standard executive and director compensation practices involving equity awards, particularly in the biotechnology and pharmaceutical industry where long-term incentives are crucial.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as part of executive and director compensation is a widespread practice in the biotechnology and pharmaceutical industry, aligning incentives with long-term shareholder value.
• A three-year vesting schedule for equity awards, as seen with these RSUs, is typical for promoting retention and sustained performance within the industry.
• The conversion of vested RSUs into common stock is a standard mechanism for directors and executives to realize their equity compensation, consistent with industry norms.

Corporate Governance

Related Party Transactions

• The conversion of Restricted Stock Units by a director is considered a related-party transaction, representing a standard compensation event reported transparently under SEC regulations.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively, signaling confidence in the company's long-term prospects.
• Employees: The RSU vesting structure is a common incentive, potentially impacting employee retention and motivation if similar plans are in place across the company.

Key Dates

Recommendation

This Form 4 reports a routine, scheduled conversion of Restricted Stock Units by a director. While it increases the director's direct beneficial ownership, which is a positive signal of alignment, it does not present new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It's an expected event under existing compensation plans.

Keywords

Novavax, NVAX, Form 4, Insider Transaction, Director Stock, Restricted Stock Units, RSU Conversion, Beneficial Ownership